Invest A/S Lundbeckfond Net Worth

The estimated Net Worth of Invest A/S Lundbeckfond is at least $4.73 Milion dollars as of 16 March 2020. Invest Lundbeckfond owns over 187,500 units of Trevi Therapeutics stock worth over $4,727,983 and over the last 7 years Invest sold TRVI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Invest Lundbeckfond TRVI stock SEC Form 4 insiders trading

Invest has made over 3 trades of the Trevi Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently Invest bought 187,500 units of TRVI stock worth $3,000,000 on 16 March 2020.

The largest trade Invest's ever made was buying 654,762 units of Trevi Therapeutics stock on 21 November 2017 worth over $9,166,668. On average, Invest trades about 405,754 units every 282 days since 2017. As of 16 March 2020 Invest still owns at least 1,432,722 units of Trevi Therapeutics stock.

You can see the complete history of Invest Lundbeckfond stock trades at the bottom of the page.

What's Invest Lundbeckfond's mailing address?

Invest's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 14TH FLOOR, NEW HAVEN, CT, 06510.

Insiders trading at Trevi Therapeutics

Over the last 5 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett oraz Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.

What does Trevi Therapeutics do?

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Complete history of Invest Lundbeckfond stock trades at scPharmaceuticals Inc, Imara Inc oraz Trevi Therapeutics

Trevi Therapeutics executives and stock owners

Trevi Therapeutics executives and other stock owners filed with the SEC include:

• Jennifer Good,
  President, Chief Executive Officer, Co-Founder, Director
• Thomas Sciascia,
  Co-Founder, Chief Medical Officer
• Jennifer L. Good,
  Co-Founder, CEO, Pres & Director
• Dr. Thomas R. Sciascia,
  Co-Founder & Chief Medical Officer
• Anne VanLent,
  Independent Director
• Edward Mathers,
  Director
• Michael Heffernan,
  Independent Director
• Dominick Colangelo,
  Director
• James Cassella,
  Independent Director
• Helena Brett-Smith,
  Chief Development Officer
• Christopher Seiter,
  Chief Financial Officer
• David Meeker,
  Independent Chairman of the Board
• Danine Summers,
  VP of Medical Affairs
• Dr. William P. Forbes Pharm. D., Pharm.D.,
  Chief Devel. Officer
• Christopher Galletta,
  Controller & Chief Accounting Officer
• Lisa Delfini,
  Chief Financial Officer
• Frank P. Muscolo,
  Exec. Officer
• Dr. William P. Forbes Pharm.D., Pharm. D.,
  Chief Devel. Officer
• Dr. Amale Hawi,
  Sr. VP of CMC
• Christopher J. Seiter,
  Chief Financial Officer
• Christopher Galletta,
  See Remarks
• Farrell Simon,
  Chief Commercial Officer
• Peter W. Sonsini,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Frank P Muscolo,
  Controller
• Group Holdings (Sbs) Adviso...,
  
• Ali Behbahani,
  10% owner
• Scott D Sandell,
  10% owner
• Yann Mazabraud,
  See Remarks
• Enterprise Associates 16, L...,
  
• Carmen Chang,
  10% owner
• Debra A Drake,
  10% owner
• William J Oshea,
  10% owner
• Fund V, L.P.Omega Fund V Gp...,
  
• David M Mott,
  10% owner
• Venture Partners Iv, L.P.Ap...,
  
• Eran Nadav,
  Director
• Invest A/S Lundbeckfond,
  10% owner
• Family Investment Co Vmfic ...,
  
• Joshua Makower,
  10% owner
• Mette Kirstine Agger,
  Director
• Peter J Barris,
  10% owner
• Anna Guyer Mitsak,
  Director
• Forest Baskett,
  10% owner
• King Mellon Foundation Richard,
  10% owner
• Paul Edward Walker,
  10% owner
• William P Forbes,
  Chief Development Officer
• Gp A, Llcbonderman Davidcou...,
  
• David J Clark,
  Chief Medical Officer
• Lisa Delfini,
  Chief Financial Officer